author-photo

R. Schlossman

University of Michigan

22

Papers

1278

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (28)
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.

2011 Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
The research mission in myeloma

2009 Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial

2009 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

2009 Leukemia
Show All
- Source
- Cite
- Save
Citations (69)
Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

2008 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (62)
A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

2005 Blood
Show All
- Source
- Cite
- Save
Citations (33)